Cutaneous manifestations of pediatric lupusArkin, Lisa M.a; Nguyen, Cordelliab; Klein-Gitelman, MarisacCurrent Opinion in Rheumatology: September 2019 - Volume 31 - Issue 5 - p 411–420 doi: 10.1097/BOR.0000000000000610 PEDIATRIC AND HERITABLE DISORDERS: Edited by Polly J. Ferguson Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review To review recent evidence on cutaneous manifestations of lupus, with a focus on evidence for pediatric patients. Recent findings Cutaneous manifestations of SLE are common and may precede signs or symptoms of systemic disease. Early recognition and initiation of therapy improves quality of life by reducing cutaneous disease activity. Antimalarials are first line for moderate-to-severe disease. Photo protection is a critical component of therapy and perhaps the only modifiable risk factor for SLE. Recognition of cutaneous vasculopathy may reduce mortality from vascular occlusion. Summary There is a critical need for better understanding of pathogenesis, risk factors and outcomes in cutaneous lupus to determine optimal treatment and surveillance strategies. Correlation of clinical phenotypes with biomarkers may help to stratify patients, optimize targeted interventions, and influence prognosis. aDepartments of Dermatology and Pediatrics bUniversity of Wisconsin School of Medicine & Public Health cDepartment of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA Correspondence to Lisa M. Arkin, MD, Department of Dermatology, University of Wisconsin School of Medicine & Public Health, One South Park Street, 7th floor, Madison, WI 53715, USA. Tel: +1 608 287 2450; fax: +1 608 287 2626; e-mail: email@example.com Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.